Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...

A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...

Treatment Blood Test Offers New Hope for Personalized Cancer Therapy DecisionsA new Yale study has found evidence to support ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of ...

This evaluation reviews the evidence for osimertinib for treating NSCLC after complete tumour resection. It also reviews new evidence collected as part of the managed access agreement, which includes ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...